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Imaging techniques frequently employ contrast agents to improve image resolution and enhance pathology detection. These gadolinium-
and iodine-based media, although generally considered safe, are associated with a number of adverse effects ranging from mild to severe.
Reactions are classified as either anaphylactoid (‘‘anaphylaxis-like’’) or nonanaphylactoid, depending on a number of elements that will be
reviewed. Herein, we have summarized predisposing risk factors for adverse events resulting from the use of contrast, their associated
pathophysiological mechanisms as well as known prophylaxis for the antitreatment of high-risk patients. In the unlikely event that a serious
adverse reaction does occur, we have provided a comprehensive summary of treatment protocols. Our goal was to thoroughly evaluate the
current literature regarding adverse reactions to radiocontrast agents and provide an up to date review for the health care provider.Resume
Les techniques d’imagerie utilisent souvent des produits de contraste pour accro^ıtre la resolution de l’image et faciliter la detection des
affections. Ces produits a base de gadolinium et d’iode, que l’on considere generalement comme etant securitaires, sont associes a un certain
nombre d’effets indesirables benignes a graves. Ces effets sont classes en tant que reactions anaphylacto€ıdes (qui rappellent l’anaphylaxie) ou
reactions non anaphylacto€ıdes, en fonction de plusieurs facteurs. Dans le cadre de la presente etude, nous avons resume les facteurs de risque
qui predisposent a des evenements indesirables lies aux produits de contraste, les mecanismes pathophysiologiques qui leur sont associes et
les mesures connues de prophylaxie destinees aux patients a risque eleve. Dans l’hypothese peu probable qu’un effet indesirable grave se
produirait, nous presentons par ailleurs une synthese globale des protocoles de traitement. Notre objectif consistait a analyser la docu-
mentation sur les effets indesirables lies a des produits de contraste radiologique et de fournir un compte rendu a jour au professionnel de la
sante.
 2016 The Authors. Published by Elsevier Inc. on behalf of Canadian Association of Radiologists. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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million procedures a year employ iodine [1]. Iodine-based
contrast agents are classified on the basis of their osmo-
lality. High-osmolar agents dissociate significantly in
aqueous solution, whereas low-osmolar agents generally
possess an osmolality slightly higher then blood. Histori-
cally, high-osmolar iodinated contrast media (CM) have
made way for low-osmolar agents, as they are less frequently
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http://dx.doi.org/10.1016/j.carj.2016.05.006contributes significantly to its risk profile due to the ability to
influence the osmolar gradient of the extracellular fluid
environment. Despite the relative safety of both ionic and
nonionic radiocontrast, adverse reactions do occur. In gen-
eral, the frequency and severity of adverse reactions to
gadolinium-based CM is significantly lower than for iodin-
ated forms. In a study accessing 456,930 contrast doses, a
total of 522 cases of adverse events were reported [2]. Of
those cases, 458 were attributed to low-osmolar iodinated
CM and only 64 to gadolinium injections. However, the
percentage of serious adverse reactions to gadolinium-based
contrast were almost double that of low-osmolar iodinated
forms. Overall rates of adverse reactions resulting from high-
osmolar contrast range from 5%-12% compared to 1%-3%Association of Radiologists. This is an open access article under the CC BY-
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the use of radiocontrast media does not differ on the basis of
ionicity [4]. Overall, the reported incidence of adverse events
with low-osmolar iodinated contrast is 1.5 events per 1000
doses (2.62% of which are serious) and 0.4 events per 1000
doses (6.25% of which are serious) with gadolinium-
containing agents [2].
Reactions to CM are either anaphylactoid or non-
anaphylactoid (chemotoxic) in origin. Although the majority
of anaphylacotid reactions to CM occur immediately,
delayed reactions have been reported [5]. Anaphylactoid, or
idiosyncratic reactions to CM, are poorly understood.
Despite possessing characteristics of anaphylaxis, there ap-
pears to be no distinct release of immunoglobulin (IgG or
IgE) antibodies specific to the radioactive agent [6]. It is
believed that intravenous administration of CM causes
allergic-like symptoms via a compensatory release of various
vasoactive compounds, initiation of the contact and com-
plement systems, the conversion of L-arginine to nitric oxide
[7,8] and the release of pseudoantigens, precipitating the
discharge of hypotensive mediators [9]. However, the release
of histamine from basophils and eosinophils is regarded to be
the most important mechanism in the pathophysiology of
anaphylactoid reactions, and likely contributes to adverse
reactions resulting from the use of high osmolar agents [7].
Cochran [1] reported that more than 90% of adverse re-
actions to nonionic CM are considered anaphylactoid. There
has been debate regarding the usefulness of skin tests for
predicting such reactions in high-risk patients. A recent study
by Kim et al [10], however, concluded that CM skin testing
was of no clinical benefit in predicting hypersensitivity to
radiologic CM.
Unlike idiosyncratic reactions, nonanaphylactoid re-
actions are dose dependent and directly influenced by the
physiochemical properties of the CM used. Ionic character-
istics of CM have the ability to disrupt neural and cardiac
signaling [3], whereas osmolarity significantly influences
fluid distribution [7]. Overall, chemotoxic reactions are
thought to result from a disturbance in homeostasis [11].
Other factors that may influence the incidence of such re-
actions include the dose and route of administration. Larger
(>100 mL iodinated contrast), intra-arterial doses areTable 1
A summary of mild, moderate, and serious anaphylactoid and nonanaphylactoid
Severity Type Reaction
Mild Anaphylactoid Limited urticaria/pruritus, limited cutaneous
conjunctivitis, rhinorrhea
Nonanaphylactoid Limited nausea/vomiting, flushing/warmth/c
self-limited vasovagal reactions
Moderate Anaphylactoid Diffuse urticaria/pruritus, diffuse erythema
hoarseness without dyspnea, wheezing/br
Nonanaphylactoid Continuous nausea/vomiting, hypertensive u
and responds to treatment
Severe Anaphylactoid Diffuse oedema, facial oedema with dyspne
hypoxia, wheezing/bronchospasm, signifi
Nonanaphylactoid Vasovagal reacting resistant to treatment, arassociated with increased risk [12]. For gadolinium agents,
standard doses generally range between 0.1-0.3 mmol/kg.
Acute adverse reactions to contrast are classified as mild,
moderate or severe. Mild adverse reactions to contrast are
noted to be self-limited and absent of progression. Moderate
reactions are more diffuse and generally require medical
management. Serious adverse reactions are considered life
threatening and requiring immediate medical attention [7]. A
complete summary of potential mild, moderate and severe
adverse reactions is provided in Table 1.
The purpose of this update is to evaluate the etiology,
prevention, and treatment of adverse reactions resulting from
the use of both ionic and nonionic CM. A summary of cur-
rent clinical research for the safe and effective uses of these
reagents will be provided. It is our hope to provide a concise
protocol for Canadian health care providers to follow.
Risk Factors
All patients should be evaluated before receiving contrast,
and any missing physical or laboratory information obtained.
This includes a thorough medical and contrast-related his-
tory, and pertinent laboratory values namely, complete blood
count, electrolyte profile, and renal function parameters. The
greatest predisposing risk factor for an adverse reaction to
CM is a previous reaction [7]. Risk of repeat reaction is as
high as 60% if patients are re-exposed to the same contrast
agent [13]. CM-related risk factors include larger dose,
increased rate of administration, the use of higher osmolar
nonionic CM, and intra-arterial (vs intravenous)
administration.
Patients with atopic tendencies, including those suffering
from asthma are at an increased risk. In an early study, it was
found that up to 11% of asthmatics reacted to ionic CM [14],
a 5.8-fold increase in incidence relative to health individuals
[4]. Although there has been much debate, those suffering
from sensitivity to seafood are not at a heightened risk for
allergic-type reactions to CM [14]. In cancer patients, it has
been proposed that the increase in circulating histamine may
point to a potential cause of anaphylactoid reactions in this
group [15]. Further yet, those suffering from multiple
myeloma are at a heightened risk due to the interactionreactions [7]
oedema, limited itchy/scatchy throat, nasal congestion, sneezing,
hills, headache, dizziness, anxiety, altered taste, mild hypertension,
with stable vitals, facial oedema without dyspnea, throat tightness or
onchospasm, mild or no hypoxia
rgency, isolated chest pain, vasovagal reaction reaction that requires
a, diffuse erythema with hypotension, laryngeal oedema with stridor and/or
cant hypoxia, anaphylactic shock (hypotension with tachycardia)
rhythmia, convulsions, seizures, hypertensive emergency
Table 4
Emergency pretreatment protocol for those to receive contrast
Option Medication Regimen
Optimal Methylprednisolone sodium
succinate: 40 mg IV
OR
Hydrocortisone sodium
succinate: 200 mg IV
þ
Diphenhydramine: 50 mg IV
Every 4 h before
administration of
contrast
1 h prior
If allergic to
methylprednisolone,
aspirin, nonsteroidal
anti-inflammatories
Dexamethasone sodium
sulfate: 7.5 mg IV
OR
Betamethasone: 6 mg IV
þ
Diphenhydramine: 50 mg IV
Every 4 h before
administration of
contrast
1 h prior
If <4-6 h prior to
contrast media
admin
Diphenhydramine: 50 mg IV 1 h prior
IV ¼ intravenous.
Table 2
A summary of common risk factors for adverse reactions to CM
Risk factors Characteristics
CM related Previous reaction, increased rate of admin,
higher dose (>100 mL), higher-osmolar
contrast, ionic vs nonionic, route of
admin (intra-arterial > intravenous)
Medical conditions Diabetes, heart disease, renal disease/
dysfunction, asthma, anxiety, dehydration,
thyroid disorders, oncological indications,
atopic tendencies, mastocytosis
Age Infants and seniors
Sex Women at a heightened risk
Concurrent Rx b-blockers, interleukin-2, nephrotoxic agents
(nonsteroidal anti-inflammatories,
methotrexate, aminoglycosides,
biguanides, hydralazine)
Hematological conditions Sickle cell disease, polycythemia,
paraproteinemias
CM ¼ contrast media.
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suffering from cardiovascular disorders are also at a
heightened risk of serious, life-threatening anaphylactoid
reactions [17]. Those presenting with systemic mastocytosis
are at a heightened risk of developing a mild immediate
reaction when exposed to an ionic or nonionic contrast
agent [6].
The use of CM can alter renal function by decreasing
glomerular filtration rate and causing renal vasoconstriction,
which provides a pathophysiological basis for injury.
Ensuring adequate hydration is essential as dehydration
significantly increases the risk of renal failure due to a
reduction in perfusion rates [18]. Nonetheless, many studies
evaluating contrast-induced nephrotoxicity following iodin-
ated contrast have failed to include a comparison group not
receiving these agents, while other studies have shown that
elevations in serum creatinine are common in patients not
receiving contrast agents [7]. These authors believe the risk
for the contrast-induced nephrotoxicity is exceedingly rare in
healthy individuals. In patients with pre-existing renal dis-
ease, and in particular an acute recent change in renal
function, this risk increases, although there is no clear
consensus as to when iodinated contrast is counter indicated.
Gadolinium-enhanced magnetic resonance has been used
as an alternative to contrast-enhanced computed tomographyTable 3
Two prophylactic treatment protocols for high-risk patients
Medication Regimen
Prednisone: 50 mg PO
þ
Diphenhydramine: 50 mg PO/IM/IV
Prednisone: 13 h, 7 h,
and 1 h prior
Diphenhydramine:
1 h prior
Methylprednisolone: 32 mg PO
þ
Diphenhydramine: 50 PO/IM/IV
Methylprednisolone: 12 h
and 2 h prior
Diphenhydramine:
1 h prior
IM ¼ intramuscular; IV ¼ intravenous; PO ¼ by mouth.due to its lack of nephrotoxicity. However, this is misleading,
as gadolinium has the potential for nephrogenic systemic
fibrosis (NSF) in patients with severe renal impairment, and
is thus no longer recommended in conventional angiography
in this subset of patients. NSF is a disease leading to fibrosis
of the skin and soft tissues, and may involve the heart, lungs,
and skeletal muscles, among others. It is generally believed
that failure to eliminate gadolinium agents via renal excre-
tion predispose them from dissociating with their parent
molecule, leading to deposition in various tissues. Patients at
risk of developing NSF include those on dialysis, end-stage
chronic kidney disease (estimated glomerular filtration rate
<30 mL/min/1.73 m2), an estimated glomerular filtration
rate from 30-40 mL/min/1.73 m2 who are not currently on
dialysis, and acute kidney injury. Agents most frequently
associated with NSF include gadodiamide, gadopentetate
dimeglumine, and gadoversetamide [7].
It has been suggested that patient anxiety may increase the
chance of adverse reaction to CM. Studies assessing whether
informed consent should be provided to patients have
concluded that it may in fact be prophylactic. Yucel et al [19]
demonstrated that by providing a brief description of po-
tential risk factors and adverse reactions, they were able to
reduce anxiety levels.
Age is another important factor to considerwhen identifying
at-risk patients. In neonates and infants, the volume of CM
agent used must be closely monitored considering low blood
volume [7]. Those of advanced age should also be closely
monitored [16], particularly due the risk of comorbidmaladies.
Patients suffering from thyroid disorders, including those
with Graves’ disease and multinodular goiter, are at a
heightening risk of developing CM induced thyrotoxicosis.
This is thought to result from altered iodine uptake due to
increases in free systemic levels. Patients should be moni-
tored carefully by attending endocrine specialist [20].
Although the American College of Radiology (ACR)
manual does not consider gender as a major risk factor for
adverse reactions to IV contrast, a recent study assessing
Table 5
Detailed management and treatment of adverse reactions to CM [7,18,26]
Symptom Notes Treatment
Urticaria - Monitor; most improve. If symptomatic
consider treatment.
- If severe, consider adding 2
1. Diphenhydramine: 1 mg/kg (max¼ 50 mg) PO/IM/IV (If IV
dose, administer slowly over 1-2 minutes)
2. Epinephrine: IM 0.3-0.5 mL of 1:1000
OR
EpiPen: IM 0.3 mL of 1:1000
Pediatric dosing of epinephrine: 0.01 mg/kg IM
Facial/laryngeal oedema - In severe; call emergency medical team
- If severely hypotensive, IV epinephrine
preferred
1. Oxygen by face mask 6-10 L/min
2. Epinephrine: IM 0.3-0.5 mL of 1:1000; can repeat every
5-10 minutes up to 1 mg total
OR
EpiPen: IM 0.3 mL of 1:1000; can repeat every 5-10
minutes up to 3, if required
Pediatric dosing of epinephrine: 0.01 mg/kg IM
OR (if severely hypotensive)
Epinephrine: IV 1-3 mL of 1:10,000 given slowly over
2-3 min; repeat 1 mg dose as needed
Bronchospasm - Continuously monitor. If progressively worse,
consider adding additional treatment 3.
- IV epinephrine preferential for severe
reactions, or if severely hypotensive
- Call emergency medical team
1. Oxygen by face mask 6-10 L/min
2. Beta-agonist (Albuterol?) inhaler: 180 mcg; can repeat 3
3. Epinephrine: IM 0.3-0.5 mL of 1:1000; can repeat every
5-10 minutes up to 1 mg total
OR
EpiPen: IM 0.3 mL of 1:1000; can repeat every 5-10
minutes up to 3, if required
Pediatric dosing of epinephrine: 0.01 mg/kg IM
OR (if severely hypotensive)
Epinephrine: IV 1-3 mL of 1:10,000 given slowly over
2-3 min; repeat 1 mg dose as needed
Hypotension with bradycardia - Usually spontaneous recovery 1. Oxygen by face mask: 6-10 L/min
2. Elevate legs
3. Saline 0.9%: 10-20 mL/kg
4. Atropine: IV 0.6e1.0 mg, saline flush; can repeat up to 3 mg
Hypotension with tachycardia - If severely hypotensive, IV epinephrine
preferred
1. Oxygen by face mask: 6-10 L/min
2. Elevate legs
3. Saline 0.9%: 10-20 mL/kg
4. Epinephrine: IM 0.3-0.5 mL of 1:1000; can repeat every
5-10 minutes up to 3, if required
OR
EpiPen: IM 0.3 mL; can repeat every 5-10 minutes up to
3, if required
Pediatric dosing of epinephrine: 0.01 mg/kg IM
OR (if severely hypotensive)
Epinephrine: IV 1-3 mL of 1:10,000 given slowly over
2-3 min;
Repeat 1 mg dose as needed
Hypertension 1. Oxygen by face mask: 6-10 L/min
2. Labetalol: IV 20 mg over 2 min; can double every 10 min
3. Flurosemide: IV 20-40 mg over 2 min
Seizures - If continuous, call emergency medical team 1. Turn patient onto side to avoid aspiration
2. Suction airway if required
3. Oxygen by face mask: 6-10 L/min
4. Lorazepam: IV 2-4 mg
Pulmonary oedema - Call emergency medical team 1. Oxygen by face mask: 6-10 L/min
2. Elevate head of bed
3. Furosemide: IV 20-40 mg over 2 min
4. Morphine: IV 1-3 mg; repeat as needed
(continued)
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Table 5 (continued )
Symptom Notes Treatment
Cardiac arrhythmia; normotensive - Generally no treatment required.
- Perform 12-lead ECG?
1. Oxygen by face mask: 6-10 L/min
Cardiac arrhythmia; hypotensive - Call emergency medical team
- If severely hypotensive, IV epinephrine
preferred
1. Oxygen by face mask: 6-10 L/min
2. Saline 0.9%: 10-20 mL/kg
3. Epinephrine: IM 0.3-0.5 mL of 1:1000; can repeat every
5-10 minutes up to 3, if required
OR
EpiPen: IM 0.3 mL of 1:1000; can repeat every 5-10
minutes up to 3, if required
Pediatric dosing of epinephrine: 0.01 mg/kg IM
OR (if severely hypotensive)
Epinephrine: IV 1-3 mL of 1:10,000 given slowly over 2-
3 min; repeat 1 mg dose as needed
Nausea/vomiting - Monitory; if unrelenting/severe administer
recommended treatment
Available antiemetic
Hypoglycemia - If patient can swallow, consider 2
- If patient cannot swallow, consider 4
1. Oxygen by face mask: 6-10 L/min
2. 4 ounces fruit juice
OR
3. Dextrose 50%: IV D50 0.5 ampule over 2 min
OR
4. Glucagon: IM 1 mg
Unresponsiveness - Call emergency medical team
- Initiate life support
IM ¼ intramuscular; IV ¼ intravenous; PO ¼ by mouth.
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CM found that women were at a heightened risk [21]. The
European Society of Urogenital Radiology (ESUR) guide-
lines also support this theory.
Concurrent medications can increase the risk of allergic
reactions to both ionic and nonionic CM. Although there re-
mains some uncertainty as to whether b-blockers increase the
incidence of idiosyncratic reactions [22], there is agreement
that treatment does predispose patients to management com-
plications if a reaction does occur [18]. Patients being treated
with interleukin-2 prior to receiving radiological contrast are
also at a heightened risk for an allergic reaction. These re-
actions tend to be delayed (>1 hour post procedure) and
generally quite serious [23]. Concurrent treatment with hy-
dralazine can promote lupus erythematosus following admin-
istration of iodine-based contrast. Coadministration of these
two drugs is thus contraindicated [24]. Other nephrotoxic
agents, including nonsteroidal anti-inflammatories (NSAIDs),
methotrexate, aminoglycosides, and bigunides, also have the
ability to work synergistically with the contrast agent to induce
renal failure. Careful consideration should be made for patients
concurrently being treated with these medications. Biguinides,
in particular, have the unique ability to induce lactic acidosis
when administered with iodinated contrast in patients with
renal dysfunction or who have other comorbidities impairing
metabolism of lactate (liver dysfunction or alcohol abuse) or
increasing anaerobic metabolism (cardiac failure, myocardial
or peripheral muscle ischemia, sepsis, or severe infection). The
ACR manual on CM suggests patients taking metformin withno renal disability or comorbidities do not require any cessa-
tion of their medication prior to receiving iodinated contrast. In
patients with no know renal disability but who suffer from
other comorbidities, metformin should be withheld 48 hours
prior to receiving contrast. Reinstatement of metformin should
be made following the assessment of renal function. Finally, in
patients with renal dysfunction, metformin should be sus-
pended prior to receiving intravenous (IV) contrast. Metformin
therapy should be reinstated following cautious follow up and
assessment of renal function [7].
CM has been noted to alter blood flow, plasma viscosity and
various red blood cell characteristics. It is believed that those
suffering from certain hematological disorders, including
sickle cell anemia, polycythemia, and paraproteinemias may
be at a heightened risk for CM induced hematological com-
plications. The etiology of such reactions is a direct result of
the hyperosmolarity and viscosity of the CM being used [25].
In older contrast safety guidelines it has suggested that
patients with confirmed or suspected pheochromocytomas
receive a- and b-blockade before receiving iodinated
contrast. Recent guidelines do not endorse this preparation as
there is little evidence to support the increase in serum
catecholamine levels in patients receiving nonionic or
gadolinium-based agents. In patients receiving direct intra-
arterial iodinated contrast, however, antitreatment with a-
and b-adrenergic agents is warranted [18].
We have provided a comprehensive summary of the dis-
cussed risk factors in Table 2. Patients to be considered high
risk include those with previous reaction to contrast, persons
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nificant morbidities, including renal impairment, those pos-
sessing multiple of the indicated risk factors, and finally
those exhibiting complications secondary to asthma. Pre-
treatment should be considered in all high-risk patients.
Pretreatment Protocols for High-Risk Patients
Prophylactic administration (either oral of intravenous) of
an H-1 receptor antagonist has been shown to reduce the risk of
urticarial, angioedema, and respiratory symptoms [7], although
this is considered secondary to steroid treatment. Table 3
provides a summary of two antitreatment protocols as rec-
ommended by the ACR and outlined in a recent review pub-
lished in the Canadian Association of Radiologists Journal
[26]. The ESUR has proposed similar recommendations [18].
Fifty milligrams oral prednisone at 13 hours, 7 hours, and
1 hour before administration of CM with the addition of
50 mg diphenyhydramine (Benadryl) given either orally or
intramuscularly (IM) 1 hour before, was first described by
Lasser et al [27] and still remains the most widely used
premedication; 32 mg methylprednisolone given orally 12
and 2 hours before may be substituted for prednisolone as
described by Greenberger and Patterson [28].
For patients requiring emergency administration of radio-
logical contrast (ie, <12 hours available for premedication
with steroids and histamine antagonists), 3 potential anti-
medication regimens are summarized (Table 4). The most
desirable of these as indicated by the ACR and described in
Greenberger et al [29] is the administration of 40 mg meth-
ylprednisolone sodium succinate or 200 mg hydrocortisone
sodium succinate IV every 4 hours until the administration of
CM. In addition, 50 mg of diphenyhydramine IV 1 hour prior
to contrast administration is recommended. In the event pa-
tients have defined allergies to methylprednisolone, acetylsa-
licylic acid, or NSAIDs, treatment option 2 is suggested.
Because the effectiveness of IV corticosteroids is negligible if
given <4-6 hours prior to receiving CM, the final option is to
provide 50 mg diphenhydramine IV 1 hour prior.
Controversy still remains regarding the effectiveness of
antimedication for the prevention of certain type of reactions,
particularly those with ‘‘allergy-like’’ characteristics.
Breakthrough reactions, although rare, do occur. The ESUR
note that mild reactions can be prevented using available
treatment protocols but physicians should remain vigilant.
The ACR provides guidelines identical to the one we have
outlined in Table 3. The European Society of Urogenital
Radiology remains impartial on this matter.
Management of Immediate Adverse Reactions
Using the ACR guidelines, the ESUR guidelines and Iyer
et al [26], we have compiled an exhaustive list of potentially
serious adverse reactions to ionic and nonionic CM. Serious
reactions are defined as those with signs and symptoms that
are often life threatening, resulting in permanent morbidity
or death if not managed appropriately [7]. A treatmentregimen for each of these possible reactions has been rec-
ommended and is outlined in Table 5.
For serious anaphylactic-like reactions, the use of epineph-
rine is required to counteract hypotension and angioedema.
Epinephrine has been noted to increase plasma levels of cyclic
adenosine monophosphate, a chemical with immunosuppres-
sive properties [30]. As previously suggested [31], we believe it
is important to have only one epinephrine concentration
immediately available to the radiologist (intended for intra-
muscular injection). By doing so, the radiology department
minimizes the potential for catastrophic dosing errors and delay
of treatment. There have been many case reports of such errors,
particularly in patients presenting with anaphylaxis to the ED.
Overdose is typically associated with tachycardia and hyper-
tension, and although most patients experience spontaneous
recovery, prolonged toxicity, and end-organ effects have been
documented. Despite best efforts, severely hypotensive patients
may require IVadministration of epinephrine. In these cases, a
dilution of 1:10,000 should be used (ie, 1 mg epinephrine
diluted in 10mL), as IVadministration is preferred over IM due
to the potential lack of perfusion in the extremities [7]. IV doses
of epinephrine should be available to the radiologist, however,
not in his or her immediate proximity as to avoid dosing
confusion. Subcutaneous injections of epinephrine are not
recommended due to the inferior time to reach peak plasma
concentrations relative to an IM route [32].
Cardiovascular reactions and seizures are very rare in
patients receiving an iodine-based contrast agent. Vasovagal
disruptions however, are more frequent and often require
attention. The use of high-osmolar CM is associated with
frequent, mild physiological reactions [7].
Reactions to gadolinium-based CM are infrequent. Urti-
caria and bronchospasm are the most common. Less serious,
more common issues that may arise are coldness, warmth
and/or pain at the injection site, nausea, headache, pares-
thesias, dizziness, and itching.
Risk Reduction
General precautions should be taken to ensure the likelihood
of serious adverse reactions isminimal. Some of thesemeasures
include the use of a nonionic contrast agent whenever possible,
making sure patients are adequately hydrated, ensuring emer-
gency equipment is available, and monitoring patients’ vital
signs in the postprocedure period [31]. Additionally, patients
should be thoroughly screened for any predisposing risk factors
(Table 2) prior to receivingCM.Patients at high risk should then
be considered for antitreatment. Patients who previously reac-
ted to CM should be very closely monitored. The contrast agent
that caused the initial reaction should not be used again.Conclusions
This review aimed to compile knowledge regarding the
etiology, prevention, and management of adverse reactions
to CM. Although serious reactions are rare, imaging
7Adverse reactions to contrast material / Canadian Association of Radiologists Journal xx (2016) 1e7departments should be adequately prepared if such an event
were to occur.
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